Skip to main content
OpenTrials
Completed

NCT Number: NCT00305955

Bilateral Refractive Amblyopia Treatment Study

The purpose of this study will be to:

* Determine the amount of visual acuity improvement with treatment of presumed bilateral refractive amblyopia * Determine the time course of visual acuity improvement with treatment

Completed

Looking for future studies?

Notify Me

Key information

Age range

3 year–10 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Duke University Eye Center

Durham, North Carolina, 27710, United States

About this study

There is a paucity of literature on bilateral amblyopia that is due to a substantial amount of refractive error (hypermetropia or astigmatism), and it is limited principally to review articles and case reports. The incidence is not known, but in one study, 4 of 830 (0.5%) children examined at the time of entry into school had bilateral amblyopia. Schoenleber et al performed a retrospective review of office records and identified 184 children with > +4.00 diopters of hypermetropia in both eyes, 12 of whom (6.5%) had bilateral amblyopia of 20/50 or worse. Ten of the 12 children (83%) improved to 20/40 or better in both eyes over a mean follow-up time of 22 months. Werner and Scott reported 6 cases of bilateral hypermetropic amblyopia with a spherical equivalent of at least +5.00 D and an initial visual acuity of 20/40 or worse in both eyes. All 5 patients with follow up improved with glasses alone, and 2 of these 5 had a most recent visual acuity worse than 20/40 in one eye with follow-up less than one year. Cavazos et al identified 218 eyes with hyperopia > +5.00 D or astigmatism >+2.00 D. Of these, 82 (38%) of the dominant eyes had an initial corrected visual acuity less than 20/25. Most improved to > 20/25, but many patients were lost to follow-up. In ongoing studies, bilateral refractive amblyopia is being evaluated in Native Americans.

  • Patients will be enrolled who have bilateral refractive error with hyperopia >+4.00 D and/or astigmatism >2.00 D and have visual acuity in each eye, measured using best correction derived from cycloplegic refraction, meeting the following criteria:
  • Using E-ETDRS testing for patients age 7 to <11 years: visual acuity 20 to 70 letters (20/40 to 20/400)
  • Using ATS HOTV testing for patients age 3 to <7 years visual acuity 20/50 to 20/400
  • Enrolled patients will be prescribed spectacles, which will be paid for by the study.
  • The patient will return for a Spectacle Baseline visit within 30 days, at which time the spectacles will be placed on the patient for the first time and binocular and monocular visual acuities will be measured.
  • Patients whose monocular acuity at the Spectacle Baseline Visit is 20/25 or better in both eyes will end the study
  • Patients whose monocular acuity at the Spectacle Baseline Visit is worse than 20/25 in at least one eye will begin a one-year period of study follow up
  • Follow-up visits are required at 5±:1 week, 13±:2 weeks, 26±:4 weeks, and 52±:4 weeks.
  • If at any follow-up visit a patient's monocular acuity is 20/25 or better in both eyes, the patient should return for the 52-week visit only and may skip the interim follow-up visits.

Sample size: The study plans to enroll 100 patients. At least 50 patients will be enrolled who have an interocular difference of less than 3 lines by ATS HOTV or less than 15 letters by E-ETDRS at the Spectacle Baseline visit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 3 to <11 years
  • Able to perform single-surrounded single optotype visual acuity using the ATS HOTV protocol for children 3 to <7 years old and using the E-ETDRS protocol for children 7 to <11 years old
  • Monocular visual acuity in each eye, measured using trial frames or phoropter with best correction derived from cycloplegic refraction, meeting the following criteria:
  • Using E-ETDRS testing for patients age 7 to <11 years: visual acuity 20 to 70 letters (20/40 to 20/400)
  • Using ATS HOTV testing for patients age 3 to <7 years acuity 20/50 to 20/400
  • Refractive error that meets at least one of the following criteria in each eye:
  • Spherical equivalent >+4.00 D
  • Astigmatism >2.00 D
  • Investigator believes that the patient's reduced visual acuity is due to bilateral, refractive amblyopia
  • Investigator not planning to prescribe occlusion, patching or any other amblyopia treatment other than spectacles at this time
  • Cycloplegic refraction and ocular examination within 2 months prior to enrollment

Exclusion criteria

  • Myopia greater than -6.00 D of spherical power in plus cylinder form
  • Ocular cause for decreased acuity in either eye; nystagmus per se will not exclude a patient from the study
  • Refractive correction (spectacles or contact lenses) in past three months and no more than one month of refractive correction ever
  • Prior treatment for amblyopia (other than the refractive correction permitted in previous exclusion criteria)
  • Prior intraocular or refractive surgery
  • Use of contact lenses during the study

Treatment and study plan

Spectacles

Device

optimal spectacle correction

Primary outcomes

  1. Visual acuity of 20/25 or better in both eyes

    Time frame: 52 weeks

Sponsors and collaborators

Lead sponsor

Jaeb Center for Health Research

Other

Collaborators

  • National Eye Institute (NEI)

Registry information

Acronym: ATS7

Important dates

Study start
2004
Primary completion
2006
Study completion
2006
First posted
Mar 22, 2006
Registry last updated
Mar 24, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.